Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an upsized underwritten public offering of 8,350,000 shares of its common stock at a price of $25.0...
- Phase 1b study of AL003 will enroll approximately 12 Alzheimer’s disease patients to assess safety, pharmacokinetics and pharmacodynamics, and monitor target specific biomarkers SOUTH SAN FRANCISCO, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a ...
Today, we will study why Alector (ALEC) is a high risk/reward opportunity in 2020. Company overview Alector, Inc. is a clinical-stage biopharmaceutical company that is leveraging immune-neurology for treating neurodegenerative diseases. To date, pharmaceutical companies have to try to re...
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it intends to offer and sell, subject to market and other conditions, 5,095,000 shares of its common stock in an u...
Co-Diagnostics (NASDAQ: CODX ) +158% readies coronavirus test . More news on: Co-Diagnostics, Inc., Trans World Entertainment Corporation, MarineMax, Inc., Stocks on the move, , Read more ...
Targeting smaller "bolt-on" acquisitions in the range of $1 billion to $5 billion, Eli Lilly (NYSE: LLY) plans to expand its research and development pipeline by acquiring a company roughly every quarter. The company's CFO made these comments during the J.P. Morgan Healthcare Confere...
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Arnon Rosenthal, Ph.D., co-founder and chief executive officer of Alector, will present a company overview at...
AL101 is the company’s second product candidate designed to increase the level of progranulin in the human brain. Progranulin has been identified as a key regulator of microglial function in the brain with strong genetic links to multiple neurodegenerative disorders. ...
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Alector Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that it has been selected for inclusion in the NASDAQ Biotechnology Index (Nasdaq: NBI), which will become effectiv...
SOUTH SAN FRANCISCO, Calif., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced the appointment of Richard Scheller, Ph.D., and Thomas Südhof, M.D., as co-chairs of the Company’...
News, Short Squeeze, Breakout and More Instantly...
--INVOKE-2 is the first global Phas e 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative stud...
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer's Associatio...
SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5 th Annual Neuro Pers...